Abstract
The in vitro activity of norfloxacin (MK366) against 477 aerobic gram-negative and gram-positive clinical isolates was compared to that of nalidixic acid, nitrofurantoin, ampicillin, cephalexin, trimethoprim, sulfamethoxazole, and the combination trimethoprim-sulfamethoxazole. Norfloxacin was more active than the other agents against all gram-negative organisms tested. Minimal inhibitory concentrations (MICs) ofPseudomonas aeruginosa were ⩽ 0.125–32 mg/l with 90 % inhibited (MIC90) by 4 mg/l; MICs of theEnterobacteriaceae includingSerratia marcescens were ⩽ 0.125–8 mg/l with an MIC90 of ⩽ 4 mg/l. There was also excellent activity against the grampositive cocci includingStaphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus and the enterococci, with MICs ⩽ 0.125–4 mg/l and an MIC90 ⩽ 4 mg/l. Only 8 of 477 organisms were norfloxacin-resistant (MIC ⩾ 16 mg/l): 3 of 100Pseudomonas aeruginosa, 3 of 10Pseudomonas maltophilia and 2 of 15Streptococcus bovis strains. In contrast, 97 % of the gram-positive cocci and 49 % of the gram-negative bacilli were nalidixic acid-resistant (MIC ⩾ 32 mg/l). Norfloxacin shows excellent activity against a wide range of bacteria and merits further study as a urinary antibacterial agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikura, T., Mitsuhashi, S.: In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrobial Agents and Chemotherapy 1980, 17: 103–108.
King, A., Warren, C., Shannon, K., Phillips, I.: In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrobial Agents and Chemotherapy 1982, 21: 604–607.
Downs, J., Andriole, V. T., Ryan, J. L.: In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistantPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1982, 21: 670–672.
Neu, H. C., Lathavikul, P.: In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrobial Agents and Chemotherapy 1982, 22: 23–27.
Gadebusch, H. H., Shungu, D. L., Weinberg, E., Chung, S. K.: Comparison of the antibacterial activity of norfloxacin (MK0366, AM715), a new organic acid, with that of other orally absorbed chemotherapeutic agents. Infection 1982, 10: 41–44.
Stamm, W. E., Counts, G. W., Wagner, K. F., Martin, D., Gregory, D., McKevitt, M., Turck, M., Holmes, K. K.: Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind placebo controlled trial. Annals of Internal Medicine 1980, 92: 770–775.
Harding, G. K. M., Ronald, A. R.: A controlled study of antimicrobial prophylaxis of recurrent urinary infection in women. New England Journal of Medicine 1974, 291: 597–601.
Ronald, A. R., Harding, G. K. M., Mathias, R.: Prophylaxis of recurring urinary tract infection in females: a comparison of nitrofurantoin with trimethoprim-sulfamethoxazole. Journal of the Canadian Medical Association 1975, 112 (suppl.): 13–16.
Harding, G. K. M., Buckwold, F. J., Marrie, T. J., Thompson, L., Light, R. B., Ronald, A. R.: Prophylaxis of recurrent urinary tract infection in female patients: efficacy of low-dose, thriceweekly therapy with trimethoprim-sulfamethoxazole. Journal of the American Medical Association 1979, 242: 1975–1977.
Harding, G. K. M., Ronald, A. R., Nicolle, L. E., Thomson, M. J., Gray, G. J.: Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women. Reviews of Infectious Diseases 1982, 4: 438–443.
Gurwith, M., Truog, K., Hinthorn, D., Liu, C.: Trimethoprim-sulfamethoxazole and trimethoprim alone for prophylaxis of infection in granulocytopenic patients. Reviews of Infectious Diseases 1982, 4: 593–601.
Bailey, R. R., Roberts, A. P., Gowet, P. E., de Wardener, H. E.: Prevention of urinary-tract infection with low-dose nitrofurantoin. Lancet 1971, ii: 1112–1114.
NCCLS, Proposed Standard: PSM-7. Standard methods for dilution antimicrobial susceptibility test for bacteria which grow aerobically. National Committee for Clinical Laboratory Standards, Villanova, PA, 1980.
Steers, E., Foltz, E. L., Graves, B. S.: An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiotic Chemotherapy 1959, 9: 307–311.
Brumfitt, W., Pursell, R.: Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole and trimethoprim in treatment of urinary infection. British Medical Journal 1972, ii: 673–676.
Koch, U. J., Schumann, K. P., Kuchler, R., Kewitz, H.: Efficacy of trimethoprim, sulfamethoxazole and the combination of both in acute urinary tract infection. Chemotherapy 1973, 19: 314–321.
Preiksaitis, J. K., Thompson, L., Harding, G. K. M., Marrie, T. J., Hoban, S., Ronald, A. R.: A comparison of the efficacy of nalidixic acid and cephalexin in bacteriuric women and their effect on fecal and periurethral carriage ofEnterobacteriaceae. Journal of Infectious Diseases 1981, 143: 603–608.
Rubin, R. H., Fang, L. S. T., Jones, S. R., Munford, R. S., Slepack, J. M., Varga, P.A., Onheiber, L., Hall, C. L., Tolkoff-Rubin, N. E.: Single-dose amoxicillin therapy for urinary tract infection. Journal of the American Medical Association 1980, 244: 561–564.
Buckwold, F. J., Ludwig, P., Harding, G. K. M., Thompson, L., Slutchuk, M., Shaw, J., Ronald, A. R.: Therapy for acute cystitis in adult women. Journal of the American Medical Association 1982, 247: 1839–1842.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haase, D., Urias, B., Harding, G. et al. Comparative in vitro activity of norfloxacin against urinary tract pathogens. Eur. J. Clin. Microbiol. 2, 235–241 (1983). https://doi.org/10.1007/BF02029524
Issue Date:
DOI: https://doi.org/10.1007/BF02029524